Tepotinib in Solid Tumors Harboring MET Alterations
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to understand efficacy of tepotinib in patients with solid cancers
harbouring c-MET amplification or exon 14 mutation who progressed after standard treatment
for metastatic disease.